Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cryopreservation changes the immune effector cell composition of peripheral blood stem cell grafts: An analysis from the DKMS and NMDP graft composition study
    Meeting Abstract

    Rücker-Braun, E.; Falk, B.; Markey, K. A.; Minderman, H.; Baldauf, H.; Heymann, N.; Uhlemann, H.; Heiduschke, L.; MacMillan, H. R.; Newell, E. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - A large, multicenter, retrospective analysis from the validate database
    Meeting Abstract

    Bewersdof, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment effectiveness with venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: An international real-world study
    Meeting Abstract

    Ghosh, N.; Lamanna, N.; Eyre, T. A.; Coombs, C. C.; Manzoor, B. S.; Brown, J. R.; Tuncer, H. H.; Ujjani, C. S.; Leslie, L. A.; Roeker, L. E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 study
    Meeting Abstract

    Horwitz, S. M.; Izutsu, K.; Mehta-Shah, N.; Cordoba, R.; Barta, S. K.; Bachy, E.; Gritti, G.; Jacobsen, E.; Kusumoto, S.; Guillermin, Y.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
    Meeting Abstract

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Unveiling the discrepancy in multiple myeloma risk classification between clinical practice and SKY92 test and the impact on survival
    Meeting Abstract

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; McKay, J. T.; Vesole, D. H.; Nooka, A. K.; Paul, B.; Hari, P. N.; Stork-Sloots, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201
    Meeting Abstract

    Andreadis, C.; Bobek, O.; Hsi, E. D.; Fenske, T. S.; Geyer, S. M.; Stiff, P. J.; Hill, B. T.; Horwitz, M.; Khimani, F.; Little, R. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter, real-world study in patients with R/R large B- cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)
    Meeting Abstract

    Crombie, J. L.; Nastoupil, L. J.; Andreadis, C.; Isufi, I.; Hunter, B.; Winter, A.; Hess, B.; Barta, S. K.; Frigault, M. J.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study
    Meeting Abstract

    Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save